{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:27:00Z","timestamp":1767907620374,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.4158\/ep.13.6.601","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T21:48:28Z","timestamp":1365198508000},"page":"601-608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Novel Endocrine Disrupter Effects of Classic and Atypical Antipsychotic Agents and Divalproex: Induction of Adrenal Hyperandrogenism, Reversible with Metformin or Rosiglitazone"],"prefix":"10.1016","volume":"13","author":[{"given":"G\u00fcl","family":"Bahtiyar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan S.","family":"Sacerdote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP.13.6.601_bb0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4088\/JCP.v66n0414","article-title":"Atypical antipsychotics and glucose homeostasis","volume":"66","author":"Bergman","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.4158\/EP.13.6.601_bb0010","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJM199311043291904","article-title":"Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy","volume":"329","author":"Isoj\u00e4rvi","year":"1993","journal-title":"N Engl J Med"},{"key":"10.4158\/EP.13.6.601_bb0015","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.biopsych.2005.10.017","article-title":"Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder","volume":"59","author":"Joffe","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.4158\/EP.13.6.601_bb0020","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/humrep\/dei505","article-title":"Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study","volume":"6","author":"Rautio","year":"2006","journal-title":"Hum Reprod"},{"key":"10.4158\/EP.13.6.601_bb0025","first-page":"211","article-title":"Insulin resistance syndrome and polycystic ovary syndrome: implications for diagnosis and treatment","volume":"47","author":"Tan","year":"2005","journal-title":"Panminerva Med"},{"key":"10.4158\/EP.13.6.601_bb0030","first-page":"1421","article-title":"Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency","volume":"75","author":"Speiser","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP.13.6.601_bb0035","first-page":"270","article-title":"Hyperinsulinemia and insulin insensitivity in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the relationship between serum leptin levels and chronic hyperinsulinemia","volume":"63","author":"Saygili","year":"2005","journal-title":"Horm Res"},{"key":"10.4158\/EP.13.6.601_bb0040","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1055\/s-2007-1001755","article-title":"Androgen-related effects on peripheral glucose metabolism in women with congenital adrenal hyperplasia","volume":"26","author":"Paula","year":"1994","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP.13.6.601_bb0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1100\/tsw.2006.23","article-title":"Androgen excess disorders in women: the severe insulin-resistant hyperandrogenic syndrome","volume":"24","author":"Rager","year":"2006","journal-title":"HAIR-AN. Scientific World Journal"},{"key":"10.4158\/EP.13.6.601_bb0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/jc.2005-1457","article-title":"Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism","volume":"91","author":"Carmina","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP.13.6.601_bb0055","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/eje.0.1330383","article-title":"Adrenal androgen production in polycystic ovary syndrome","volume":"133","author":"McKenna","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP.13.6.601_bb0060","first-page":"1900","article-title":"Ovarian hyperandrogenism is associated with insulin resistance to both peripheral carbohydrate and whole-body protein metabolism in postpubertal young females: a metabolic study","volume":"83","author":"Mauras","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP.13.6.601_bb0065","unstructured":"Sacerdote A, Vergara R, Carnegie B. Do all patients with NIDDM have late-onset congenital adrenal hyperplasia? In: Program and abstracts of the 76th Annual Meeting of The Endocrine Society; June 15-18, 1994; Anaheim, CA. Abstract 350."},{"key":"10.4158\/EP.13.6.601_bb0070","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2337\/diacare.18.2.278b","article-title":"Adrenal androgens and NIDDM","volume":"18","author":"Sacerdote","year":"1995","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.6.601_bb0075","unstructured":"Osehobo E, Shaw I, Sacerdote A. Do insulin sensitizers repair the gene defects in non-classical congenital adrenal hyperplasia? In: Program and abstracts of the 82nd Annual Meeting of The Endocrine Society; June 21-24, 2000; Toronto, Canada. Abstract 547."},{"key":"10.4158\/EP.13.6.601_bb0080","unstructured":"Sacerdote A. Weight-dependent expression of non-classical aldosterone synthase deficiency. In: Program and abstracts of the 84th Annual Meeting of The Endocrine Society; June 19-22, 2002San Francisco, CA. Abstract 599."},{"key":"10.4158\/EP.13.6.601_bb0085","unstructured":"Sacerdote AS, Sanchez JU, Ogbeide O, Slabodkina L. Modification of expression of non-classical congenital adrenal hyperplasia by rosiglitazone. In: Program and abstracts of the 85th Annual Meeting of The Endocrine Society; June 19-22, 2003 Philadelphia, PA. Abstract 444."},{"key":"10.4158\/EP.13.6.601_bb0090","unstructured":"Sacerdote AS. Modification of expression of non-classical congenital adrenal hyperplasia by pioglitazone. Abstract presented at: 86th Annual Meeting of The Endocrine Society; June 16-19, 2004; New Orleans, LA. Abstract 569."},{"key":"10.4158\/EP.13.6.601_bb0095","first-page":"2611","article-title":"Newly proposed hormonal criteria via genotypic proof for type II 3betahydroxysteroid dehydrogenase deficiency","volume":"87","author":"Lutfallah","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP.13.6.601_bb0100","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1210\/jc.2003-030934","article-title":"The hormonal phenotype of nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency","volume":"89","author":"Carbunaru","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP.13.6.601_bb0105","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1080\/10611860600845397","article-title":"Molecular design and delivery of siRNA","volume":"14","author":"Inoue","year":"2006","journal-title":"J Drug Target"},{"key":"10.4158\/EP.13.6.601_bb0110","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jcem.87.4.8398","article-title":"Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia\/insulin resistance","volume":"87","author":"Arslanian","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP.13.6.601_bb0115","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/edrv.20.4.0374","article-title":"The insulin-related ovarian regulatory system in health and disease","volume":"20","author":"Poretsky","year":"1999","journal-title":"Endocr Rev"},{"key":"10.4158\/EP.13.6.601_bb0120","doi-asserted-by":"crossref","first-page":"851","DOI":"10.7326\/0003-4819-97-6-851","article-title":"Insulin resistance associated with androgen excess in women with autoantibodies to the insulin receptor","volume":"97","author":"Taylor","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP.13.6.601_bb0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0015-0282(16)60060-2","article-title":"The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism","volume":"50","author":"Barbieri","year":"1988","journal-title":"Fertil Steril"},{"key":"10.4158\/EP.13.6.601_bb0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jcb.10492","article-title":"Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis","volume":"89","author":"Wang","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.4158\/EP.13.6.601_bb0135","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1210\/jc.2005-0469","article-title":"Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production","volume":"90","author":"Seto-Young","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP.13.6.601_bb0140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1677\/joe.0.1810355","article-title":"Modulation of steroidogenic enzymes by orphan nuclear transcriptional regulation may control diverse production of cortisol and androgens in the human adrenal","volume":"181","author":"Kelly","year":"2004","journal-title":"J Endocrinol"},{"key":"10.4158\/EP.13.6.601_bb0145","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2337\/diacare.23.8.1154","article-title":"Bromocriptine: a novel approach to the treatment of type 2 diabetes","volume":"23","author":"Pijl","year":"2000","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.6.601_bb0150","first-page":"531","article-title":"Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia [article in French]","volume":"15","author":"Lombertie","year":"1995","journal-title":"Ann Med Psychol (Paris)"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20428071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20428071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/GGJ5200215107765.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:48:13Z","timestamp":1761515293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20428071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S1530891X20428071"],"URL":"https:\/\/doi.org\/10.4158\/ep.13.6.601","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Endocrine Disrupter Effects of Classic and Atypical Antipsychotic Agents and Divalproex: Induction of Adrenal Hyperandrogenism, Reversible with Metformin or Rosiglitazone","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.13.6.601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}